相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Diego Chowell et al.
NATURE BIOTECHNOLOGY (2022)
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
Jeppe Sejero Holm et al.
NATURE COMMUNICATIONS (2022)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Immunoscore: a novel prognostic tool. Association with clinical outcome, response to treatment and survival in several malignancies
Silverio Ros-Martinez et al.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2020)
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Daniel K. Wells et al.
CELL (2020)
Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Cinzia Solinas et al.
TRANSLATIONAL ONCOLOGY (2020)
New biomarkers for checkpoint inhibitor therapy
Nikki Burdett et al.
ESMO OPEN (2020)
A random forest based biomarker discovery and power analysis framework for diagnostics research
Animesh Acharjee et al.
BMC MEDICAL GENOMICS (2020)
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Dan Sha et al.
CANCER DISCOVERY (2020)
Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis
Huayu Yang et al.
FRONTIERS IN ONCOLOGY (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Ida Viller Tuxen et al.
CLINICAL CANCER RESEARCH (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Christian U. Blank et al.
NATURE MEDICINE (2018)
The significance of intertumor and intratumor heterogeneity in liver cancer
Jinping Liu et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Defining the clonality of peripheral T cell lymphomas using RNA-seq
Scott D. Brown et al.
BIOINFORMATICS (2017)
NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data
Vanessa Jurtz et al.
JOURNAL OF IMMUNOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Martin Lauss et al.
NATURE COMMUNICATIONS (2017)
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
Alexandra Snyder et al.
PLOS MEDICINE (2017)
MuPeXI: prediction of neo-epitopes from tumor sequencing data
Anne-Mette Bjerregaard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley et al.
CLINICAL CANCER RESEARCH (2017)
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Zuguang Gu et al.
BIOINFORMATICS (2016)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
The cancer immunogram
Christian U. Blank et al.
SCIENCE (2016)
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome
Joseph M. Obeid et al.
ONCOIMMUNOLOGY (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
MiXCR: software for comprehensive adaptive immunity profiling
Dmitriy A. Bolotin et al.
NATURE METHODS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)
Alessandra Cesano
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Personalized oncology: genomic screening in phase 1
Ida Viller Tuxen et al.
APMIS (2014)
OptiType: precision HLA typing from next-generation sequencing data
Andras Szolek et al.
BIOINFORMATICS (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
RazerS 3: Faster, fully sensitive read mapping
David Weese et al.
BIOINFORMATICS (2012)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
分享论文
